Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.26
OTCPK:MRNA's Cash-to-Debt is ranked lower than
92% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. OTCPK:MRNA: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:MRNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 59.58 Max: No Debt
Current: 0.26
Equity-to-Asset 0.20
OTCPK:MRNA's Equity-to-Asset is ranked lower than
86% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OTCPK:MRNA: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:MRNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -2  Med: 0.59 Max: 0.95
Current: 0.2
-2
0.95
Piotroski F-Score: 3
Altman Z-Score: -65.59
Beneish M-Score: -4.86
WACC vs ROIC
25.06%
-740.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -504.60
OTCPK:MRNA's Operating Margin % is ranked lower than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. OTCPK:MRNA: -504.60 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:MRNA' s Operating Margin % Range Over the Past 10 Years
Min: -2259.18  Med: -443.64 Max: -17.26
Current: -504.6
-2259.18
-17.26
Net Margin % 189.20
OTCPK:MRNA's Net Margin % is ranked higher than
98% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. OTCPK:MRNA: 189.20 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:MRNA' s Net Margin % Range Over the Past 10 Years
Min: -2269.84  Med: -257.57 Max: 490.74
Current: 189.2
-2269.84
490.74
ROE % 123.60
OTCPK:MRNA's ROE % is ranked higher than
99% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. OTCPK:MRNA: 123.60 )
Ranked among companies with meaningful ROE % only.
OTCPK:MRNA' s ROE % Range Over the Past 10 Years
Min: -539.78  Med: -329.36 Max: 123.6
Current: 123.6
-539.78
123.6
ROA % 12.81
OTCPK:MRNA's ROA % is ranked higher than
93% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OTCPK:MRNA: 12.81 )
Ranked among companies with meaningful ROA % only.
OTCPK:MRNA' s ROA % Range Over the Past 10 Years
Min: -158.44  Med: -78.17 Max: 39.7
Current: 12.81
-158.44
39.7
3-Year Revenue Growth Rate -59.40
OTCPK:MRNA's 3-Year Revenue Growth Rate is ranked lower than
86% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. OTCPK:MRNA: -59.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:MRNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -72.9  Med: -32.9 Max: 72
Current: -59.4
-72.9
72
3-Year EPS without NRI Growth Rate -41.80
OTCPK:MRNA's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OTCPK:MRNA: -41.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:MRNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.1  Med: -21.75 Max: 102.4
Current: -41.8
-82.1
102.4
GuruFocus has detected 6 Warning Signs with Marina Biotech Inc $OTCPK:MRNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:BDSI, NAS:CASC, AMEX:BTX, NAS:BSTC, NAS:ANIP, NAS:BCRX, NAS:BMRN » details
Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 0.90
MRNA's Price-to-Owner-Earnings is ranked higher than
98% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. MRNA: 0.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRNA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.74  Med: 4.25 Max: 9.7
Current: 0.9
0.74
9.7
PB Ratio 5.32
MRNA's PB Ratio is ranked lower than
64% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. MRNA: 5.32 )
Ranked among companies with meaningful PB Ratio only.
MRNA' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.62 Max: 387.5
Current: 5.32
0.45
387.5
PS Ratio 14.71
MRNA's PS Ratio is ranked lower than
52% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. MRNA: 14.71 )
Ranked among companies with meaningful PS Ratio only.
MRNA' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 5.64 Max: 70.12
Current: 14.71
0.49
70.12
EV-to-EBIT 4.26
MRNA's EV-to-EBIT is ranked higher than
79% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. MRNA: 4.26 )
Ranked among companies with meaningful EV-to-EBIT only.
MRNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.9  Med: -1 Max: 15.3
Current: 4.26
-13.9
15.3
EV-to-EBITDA 4.26
MRNA's EV-to-EBITDA is ranked higher than
81% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. MRNA: 4.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.6  Med: -1 Max: 15.3
Current: 4.26
-14.6
15.3
Current Ratio 0.06
MRNA's Current Ratio is ranked lower than
99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MRNA: 0.06 )
Ranked among companies with meaningful Current Ratio only.
MRNA' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.24 Max: 21.21
Current: 0.06
0.03
21.21
Quick Ratio 0.06
MRNA's Quick Ratio is ranked lower than
99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MRNA: 0.06 )
Ranked among companies with meaningful Quick Ratio only.
MRNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.23 Max: 21.07
Current: 0.06
0.03
21.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.80
MRNA's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. MRNA: -17.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -155.1  Med: -22.4 Max: -2.1
Current: -17.8
-155.1
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.50
MRNA's Price-to-Median-PS-Value is ranked lower than
83% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. MRNA: 2.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.56 Max: 22.1
Current: 2.5
0.1
22.1
Earnings Yield (Greenblatt) % 23.45
MRNA's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. MRNA: 23.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.5  Med: 78.4 Max: 182.9
Current: 23.45
6.5
182.9

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.20
Beta3.02
Short Percentage of Float8.22%
52-Week Range $0.08 - 0.52
Shares Outstanding (Mil)89.77
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 
MDRNA Inc. Reports Operating Results (10-Q) Jul 30 2009 
MDRNA Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research... Mar 29 2017
Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual... Mar 24 2017
Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at... Mar 13 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 06 2017
Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on... Mar 02 2017
Marina Biotech to Participate in the 29th Annual ROTH Conference Mar 01 2017
Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel Feb 28 2017
Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer Feb 21 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors... Feb 14 2017
Marina Biotech Announces Key Additions to its Executive Management Team Feb 14 2017
Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share Feb 10 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Feb 09 2017
Marina Biotech Announces a License Agreement to SMARTICLES Feb 07 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 03 2017
MARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets,... Jan 27 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 09 2017
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events Jan 04 2017
Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing Jan 03 2017
Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase Dec 27 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)